Zoltán Szekanecz
Debreceni Egyetem
H-index: 80
Europe-Hungary
Top articles of Zoltán Szekanecz
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Granulomatosis with polyangiitis or its mimic? A case report | Journal of International Medical Research | Tamás Major Gábor Nagy Judit Szabó Huba Mózes Gabriella Szűcs | 2024/4 |
A novel way to evaluate autoantibody interference in samples with mixed antinuclear antibody patterns in the HEp-2 cell based indirect immunofluorescence assay and comparison … | Clinica Chimica Acta | Gábor Nagy Róza Földesi István Csípő Tünde Tarr Gabriella Szűcs | 2024/1/15 |
Distinct subsets of anti-pulmonary autoantibodies correlate with disease severity and survival in severe COVID-19 patients | GeroScience | Emese Tóth Miklós Fagyas Béla Nagy Jr Ivetta Mányiné Siket Blanka Szőke | 2024/4 |
Six-Month Follow-Up of Periodontal Condition in Rheumatoid Arthritis and Ankylosing Spondylitis Arthritis Patients Undergoing Anti-Tumour Necrosis Factor-α Therapy | Journal of Clinical Medicine | Ildikó Tar Edit Végh Renáta Martos Boglárka Soós Ildikó Márton | 2024/1/13 |
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician | Zoltán Szekanecz Maya H Buch Christina Charles-Schoeman James Galloway George A Karpouzas | 2024/1/12 | |
Natural Autoantibodies in Biologic-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients: Associations with Vascular Pathophysiology | International Journal of Molecular Sciences | Diána Simon Dorottya Kacsándi Anita Pusztai Boglárka Soós Edit Végh | 2024/3/18 |
Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines | Daniel H Zimmerman Zoltan Szekanecz Adrienn Markovics Kenneth S Rosenthal Roy E Carambula | 2024/3/6 | |
Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases | Peter C Taylor Ernest Choy Xenofon Baraliakos Zoltan Szekanecz Ricardo M Xavier | 2024/2/1 | |
Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids | Rheumatology | Linda Hartman José AP da Silva Frank Buttgereit Maurizio Cutolo Daniela Opris-Belinski | 2023/5/1 |
OP0045 eular points to consider on the initiation of targeted therapies in patients with inflammatory arthritides and a history of cancer | E Sebbag K Lauper J Molina Collada D Aletaha J Askling | 2023/6/1 | |
Should ACR/EULAR criteria be revised changing the RF and ACPA scores? | Guenter Steiner Lieve Van Hoovels Dóra Csige Mariele Gatto Annamaria Iagnocco | 2023/8/24 | |
One Step Back from Bedside to the Bench—How Do Different Arterial Stiffness Parameters Behave in Relation to Peripheral Resistance? | Diagnostics | Nóra Obajed Al-Ali Sára Rebeka Tóth László Váróczy László Imre Pinczés Pál Soltész | 2023/9/9 |
IMMUNE-RELATED ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITORS: THE DEBRECEN EXPERIENCE | Reumatizam | Zoltán Szekanecz Enikő Sebestyén Nóra Major Levente Bodoki Attila Makai | 2023/10/16 |
A JAK-gátlók biztonságossága rheumatoid arthritisben–amit a gyakorló klinikusnak tudni érdemes. | Immunology Quaterly/Immunologiai Szemle | SZEKANECZ ZOLTÁN | 2023/12/1 |
Tocilizumab in Combination with Corticosteroids in COVID-19 Pneumonia: A Single-Centre Retrospective Controlled Study | Biomedicines | Zsófia Kardos Miklós Szabó Zsuzsanna Baráth Ágnes Miksi Csaba Oláh | 2023/1/26 |
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of … | Annals of the rheumatic diseases | Christina Charles-Schoeman Maya H Buch Maxime Dougados Deepak L Bhatt Jon T Giles | 2023/1/1 |
Corrigendum: Editorial: Reviews in rheumatology | Frontiers in Medicine | Yves Henrotin Zoltan Szekanecz Kayo Masuko | 2023/3/29 |
Waning of SARS-Cov-2 vaccine effectiveness against delta variant in COPD patients | Lorinc Polivka Istvan Valyi-Nagy Zoltan Szekanecz Krisztina Bogos Hajnalka Vago | 2023/4/20 | |
POS0824 CARDIOVASCULAR (CV) AND MALIGNANCY EVENTS IN THE FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) CLINICAL DEVELOPMENT PROGRAM UP TO 8.3 YEARS | X Mariette S Borchmann S Aspeslagh J Calvo R Moriggl | 2023/6/1 | |
A gyulladásos betegségek célzott terápiájának jövôbeli lehetôségei. | SZEKANECZ ZOLTÁN | 2023/7/1 |
Co-Authors
